Volume 10 Supplement 1
Analysis of indoleamine 2,3-dioxygenase 1 (IDO1) expression of cultured cord blood adherent mononuclear cells as an indicator of atopic risk
© Zhu et al; licensee BioMed Central Ltd. 2014
Published: 3 March 2014
Maternal atopy is a known risk factor for allergy development in children. This link can be studied to find potential indicators of atopic risk by examining umbilical cord blood. Indoleamine 2,3-dioxygenase 1 (IDO1), the initiator of the IDO pathway, plays a regulatory role in the immune response and may differ in expression in the adherent mononuclear cells (AMNC) of atopic and non-atopic individuals. Supernatants of these AMNC cultures may also exhibit different cytokine profiles.
Cord blood samples were collected from consenting women undergoing elective Caesarian-sections and atopic status was self-reported. Mononuclear cells were isolated and cryopreserved. Once thawed, AMNCs were cultured and stimulated with interferon-gamma (IFN-γ 1μg/ml or 1ng/ml) with or without control standard endotoxin (CSE 10ng/ml). In each condition, 7.5x106 cells were seeded for gene analysis and 5x106 cells were seeded for cytokine analysis. Cells were lysed for RNA isolation, reverse transcribed and cDNA levels were analyzed using qPCR. Supernatant cytokine levels were analyzed using the Luminex® xMAPTM Technology.
Preliminary differences detected suggest that further research could elucidate a suitable biomarker to predict atopic risk. Due to the lack of significant differences between high and low atopic risk groups for IDO1 expression and cytokine expression, a reliable biomarker was not determined in this study.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.